News

The arrangement builds on a partnership with the Biomedical Advanced Research and Development Authority (BARDA) established in 2020. BARDA is part of the Administration for Strategic Preparedness and

The submission seeks approval for patients diagnosed with unresectable or metastatic melanoma whose condition has progressed following at least two previous systemic treatments, including anti- programmed death-1 (PD-1)

Under the partnership, the platform will be applied to haematoxylin and eosin-stained whole-slide images to profile tumour microenvironment characteristics. The companies plan to utilise the tool to identify

The transaction values the US-based biotechnology company at approximately $3bn post-money. Bristol Myers Squibb (BMS) led the funding round, with further capital provided by existing investors. Pathos AI

The partnership focuses on evaluating digital patient twins, which are computer-based models of individual patients constructed from clinical and related data. The companies intend to examine whether these

The financial package includes an upfront payment alongside milestone payments tied to specific development, regulatory, and commercial targets. Royalties on net sales remain separate from the package. Kaigene

Under the deal, AI Proteins is set to receive an upfront cash sum of more than $400m to design and optimise de novo miniproteins directed at targets selected

The clearance permits the therapies to be administered before radical cystectomy as neoadjuvant therapy and continued following surgery as adjuvant treatment. Applicable to patients irrespective of cisplatin eligibility,

The regulatory decision represents the first new drug application (NDA) approval secured by the speciality pharmaceutical manufacturer. Cosette expects the therapy to be commercially accessible in the US